CN112076199A - 一种降血糖降血脂和降血胆固醇方剂 - Google Patents

一种降血糖降血脂和降血胆固醇方剂 Download PDF

Info

Publication number
CN112076199A
CN112076199A CN201910558795.0A CN201910558795A CN112076199A CN 112076199 A CN112076199 A CN 112076199A CN 201910558795 A CN201910558795 A CN 201910558795A CN 112076199 A CN112076199 A CN 112076199A
Authority
CN
China
Prior art keywords
diosgenin
acid
blood
arctiin
alisol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910558795.0A
Other languages
English (en)
Inventor
谢亚坚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201910558795.0A priority Critical patent/CN112076199A/zh
Publication of CN112076199A publication Critical patent/CN112076199A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种降血糖降血脂和降血胆固醇方剂，从我国卫健委公布的食用中药和可作保健品中药中提取有效成分构成方剂，本方剂无毒副作用，可以放心服用，所利用的中药成分有齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β‑谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮等制作有粉剂、颗粒剂、片剂和胶囊剂。

Description

一种降血糖降血脂和降血胆固醇方剂
技术领域：
本发明涉及心脑血管疾病领域，特别涉及一种降低血糖血脂和血胆固醇方剂。
背景技术：
心脑血管疾病是一种威胁人类，特别是中老年人健康的常见病，全世界每年死于心脑血管疾病人数高达2000万人，我国每年死于心脑血管疾病者也有400万人，占我国每年死亡病因的51％，我国有糖尿病患者超过1.14亿人，糖尿病的危险在于其并发症，如并发周围神经病变和心脑神经病变，并发冠心病、肾毒症、致盲、糖尿病足(截肢)，甚至并发难以发现和无法治愈的胰腺癌等。全球有5亿多糖尿病患者，因糖尿病并发症的死亡人数每年有300万人。有一种不易被注意的高血糖，被称为“糖尿病前期”，则空腹血糖为6.1-6.9 之间(空腹血糖为7.0或以上为糖尿病)，这个人群在我国有 4亿之众，全球有近20亿人，这是糖尿病患者的“巨大后备军团”，离糖尿病只有一步之遥，中西医都不作为治疗对象，则中西医都束手无策。
我国高血脂患者有1.6亿人，高血胆固醇者有近1亿人。
高血脂和高血胆固醇通常会引发高血压，严重会引发中风(脑猝中)。国家卫健委再生医学实验室副主任指出：高血脂是“冠心病心肌梗死、心脑性猝死和缺血性脑猝中的独立而重要的危险因素，被称为沉默的杀手。研究显示，血胆固醇每升高1％，冠心病发病率增加2％-3％。
根据以上所述，需要研发一种具有降血糖降血脂和降血胆固醇方剂。
发明内容：
我国卫健委公布了100多种可食用中药和可作保健品中药。本发明利用其中一部分具有降血糖降血脂和降血胆固醇的中药提取有效成分构成方剂，由于利用的是可食用材料和保健品材料，因此无毒副作用，既具有治疗效果又具有保健功能，高血糖人群和高血脂高血胆固醇人群都可放心服用。
本发明从可食用中药和可作保健品中药中提取具有降血糖降血脂和降血胆固醇的有效成分，提取的有效成分是：齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮。
优选地，将优选地，将齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮等混合为粉剂，用柠檬水送服，则获得降血糖降血脂和降血胆固醇的效果。
优选地，将齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮等制作成颗粒剂，获得降血糖降血脂和降血胆固醇颗粒剂。
优选地，将齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮等制作成口服片剂，获得降血糖降血脂和降血胆固醇口服片剂。
优选地，将齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮等制作成胶囊剂，获得降血糖降血脂和降血胆固醇胶囊剂。
具体实施方式：
下面结合具体实施例就本发明的“一种降血糖降血脂和降血胆固醇方剂”作进一步的说明。应当理解，以下所述的具体实施例，仅仅用于解释本发明，并不用于限制本发明。
实施例1
将齐墩果酸1500毫克，山奈酚800毫克、牛膝甾酮600 毫克、蜕皮甾400毫克、梓醇800毫克、地黄苷800毫克、槲皮素600毫克、薏苡素600毫克、芍药苷600毫克、甜菜碱400毫克、中肌醇200毫克、泽泻醇A100毫克、泽泻醇 A单酸脂100毫克、姜黄素400毫克、柴胡皂苷200毫克、芝麻素600毫克、薯蓣皂苷400毫克、牛蒡苷200毫克、丹参素200毫克、薯蓣皂苷元200毫克、罗布麻素200毫克、昆布素200毫克、β-谷甾醇200毫克、甘草酸200毫克共混合为粉剂，用柠檬水送服，可获得降血糖降血脂和降血胆固醇效果。
实施例2
将齐墩果酸2000毫克，山奈酚1000毫克、牛膝甾酮800 毫克、蜕皮甾600毫克、梓醇1000毫克、地黄苷1000毫克、槲皮素800毫克、薏苡素800毫克、甜菜碱800毫克、芍药苷800毫克、泽泻醇A200毫克、泻醇A单酸脂200毫克、姜黄素600毫克、柴胡皂苷400毫克、芝麻素1000毫克、薯蓣皂苷800毫克、牛蒡苷400毫克、丹参素400毫克、薯蓣皂苷元800毫克、牛蒡苷400毫克、昆布素400毫克、罗布麻素400毫克、β-谷甾醇400毫克、甘草酸400毫克、柠檬酸200毫克、柠檬苦素100毫克、柠檬黄酮100毫克共混合制成颗粒剂，可获得降血糖降血脂和降血胆固醇的棵粒剂。
实施例3
将齐墩果酸1600毫克，山奈酚800毫克、牛膝甾酮600 毫克、蜕皮甾400毫克、梓醇800毫克、地黄苷800毫克、槲皮素600毫克、薏苡素600毫克、甜菜碱600毫克、中肌醇200毫克、芍药苷600毫克、泽泻醇A100毫克、泽泻醇 A单酸脂100毫克、姜黄素400毫克、柴胡皂苷200毫克、芝麻素800毫克、薯蓣皂苷600毫克、牛蒡苷200毫克、丹参素200毫克、罗布麻素200毫克、薯蓣皂苷元400毫克、昆布素200毫克、β-谷甾醇200毫克、甘草酸200毫克、柠檬酸100毫克、柠檬苦素50毫克、柠檬黄酮50毫克共混合制成降血糖降血脂和降血胆固醇的口服片剂。
实施例4
将齐墩果酸3000毫克，山奈酚1500毫克、牛膝甾酮1200 毫克、蜕皮甾800毫克、梓醇1500毫克、地黄苷1500毫克、槲皮素1200毫克、薏苡素1200毫克、甜菜碱1200毫克、中肌醇800毫克、芍药苷1200毫克、泽泻醇A200毫克、泽泻醇A单酸脂200毫克、姜黄素800毫克、柴胡皂苷400毫克、芝麻素1500毫克、薯蓣皂苷1000毫克、牛蒡苷600毫克、罗布麻素600毫克、丹参素600毫克、薯蓣皂苷元600 毫克、昆布素600毫克、β-谷甾醇600毫克、甘草酸600 毫克、柠檬酸300毫克、柠檬苦素150毫克、柠檬黄酮150 毫克共混合制成降血糖降血脂和降血胆固醇的口服胶囊剂。
以上所述仅为本发明的优选实施例，并非因此限制本发明的专利范围，凡是利用本发明说明书所作的等效结构变换，或直接或间接运用在其他相关的技术领域，均同理包括在本发明的专利保护范围内。

Claims (5)

1.一种降血糖降血脂和降血胆固醇方剂，包括粉剂、颗粒剂、片剂和胶囊剂。其特色在于，利用我国卫健委公佈的药食两用中药和可作保健品中药，提取其中具有降血糖降血脂和降血胆固醇的有效成分构成方剂，无毒副作用，可放心服用。所提取的有效成分是：齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮，所得产品有粉剂、颗粒剂、片剂和胶囊剂。
2.如权利要求1所述的一种降血糖降血脂和降血胆固醇方剂，其特征在于，将齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸共混合成粉剂，用柠檬水送服，达到降血糖降血脂和降血胆固醇效果。
3.如权利要求1所述的一种降血糖降血脂和降血胆固醇方剂，其特征在于，将齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮混合制作成颗粒剂，获得降血糖降血脂和降血胆固醇颗粒剂。
4.如权利要求1所述的一种降血糖降血脂和降血胆固醇方剂，其特征在于，将齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮等制作成胶片剂，获得降血糖降血脂和降血胆固醇片剂。
5.如权利要求1所述的一种降血糖降血脂和降血胆固醇方剂，其特征在于，将齐墩果酸、山奈酚、牛膝甾酮、蜕皮甾、梓醇、地黄苷、槲皮素、薏苡素、芍药苷、甜菜碱、中肌醇、泽泻醇A、泽泻醇A单酸脂、姜黄素、柴胡皂苷、芝麻素、薯蓣皂苷、牛蒡苷、丹参素、薯蓣皂苷元、罗布麻素、昆布素、β-谷甾醇、甘草酸、柠檬酸、柠檬苦素和柠檬黄酮等制作成胶囊剂，获得降血糖降血脂和降血胆固醇胶囊剂。
CN201910558795.0A 2019-06-13 2019-06-13 一种降血糖降血脂和降血胆固醇方剂 Pending CN112076199A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910558795.0A CN112076199A (zh) 2019-06-13 2019-06-13 一种降血糖降血脂和降血胆固醇方剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910558795.0A CN112076199A (zh) 2019-06-13 2019-06-13 一种降血糖降血脂和降血胆固醇方剂

Publications (1)

Publication Number Publication Date
CN112076199A true CN112076199A (zh) 2020-12-15

Family

ID=73734410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910558795.0A Pending CN112076199A (zh) 2019-06-13 2019-06-13 一种降血糖降血脂和降血胆固醇方剂

Country Status (1)

Country Link
CN (1) CN112076199A (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687460A (zh) * 2014-07-29 2017-05-17 深圳君圣泰生物技术有限公司 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用
CN107982318A (zh) * 2017-12-13 2018-05-04 广西中医药大学 一种降血糖的中药复方组合物
CN108619438A (zh) * 2018-07-31 2018-10-09 谢亚坚 一种中药降血糖方剂
CN108635549A (zh) * 2018-08-02 2018-10-12 谢亚坚 一种中药降低血脂方剂
CN108653529A (zh) * 2018-08-06 2018-10-16 谢亚坚 一种中药降低血胆固醇方剂
CN109364084A (zh) * 2018-11-27 2019-02-22 深圳市绘云生物科技有限公司 一种治疗血糖、血脂异常及神经退行性疾病的药物及其制剂

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687460A (zh) * 2014-07-29 2017-05-17 深圳君圣泰生物技术有限公司 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用
CN107982318A (zh) * 2017-12-13 2018-05-04 广西中医药大学 一种降血糖的中药复方组合物
CN108619438A (zh) * 2018-07-31 2018-10-09 谢亚坚 一种中药降血糖方剂
CN108635549A (zh) * 2018-08-02 2018-10-12 谢亚坚 一种中药降低血脂方剂
CN108653529A (zh) * 2018-08-06 2018-10-16 谢亚坚 一种中药降低血胆固醇方剂
CN109364084A (zh) * 2018-11-27 2019-02-22 深圳市绘云生物科技有限公司 一种治疗血糖、血脂异常及神经退行性疾病的药物及其制剂

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
何洪英，等: "调节血脂保健食品的研究进展", 《食品与机械》 *
容欧，等: "柠檬精深加工研究现状", 《现代食品》 *
李强，等: "《新编常用中药有效成分手册》", 31 January 2008, 中国协和医科大学出版社 *
沈怡芸: "夹竹桃麻素对早期Ⅱ型糖尿病肾病小鼠肾脏的保护作用的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *
马伟光，等: "《云南民族药防治皮肤病的研究与应用》", 31 December 2014, 云南科技出版社 *

Similar Documents

Publication Publication Date Title
Rodriguez-Fragoso et al. Risks and benefits of commonly used herbal medicines in Mexico
Kumar et al. The genus Crataegus: chemical and pharmacological perspectives
Nugroho et al. Anti-diabetic effect of a combination of andrographolide-enriched extract of Andrographis paniculata (Burm f.) Nees and asiaticoside-enriched extract of Centella asiatica L. in high fructose-fat fed rats
US11125130B2 (en) Medicinal composition of extract of seed of Emblica officinalis and method of preparing the same
Marchyshyn et al. Hypoglycemic effect of Cyperus esculentus L. tubers extract
CN102430090A (zh) 一种藏药如意珍宝组合物制剂及其制备方法
Jalili et al. An overview of therapeutic potentials of Taraxacum officinale (dandelion): A traditionally valuable herb with a reach historical background
Kumar et al. Honey infused with herbs: A boon to cure pathological diseases
CN104523742B (zh) 一种具有护肝和提高免疫作用的多糖组合物及其应用
CN104055947A (zh) 一种含有葡萄提取物的中药组合物及制备方法
CN112076199A (zh) 一种降血糖降血脂和降血胆固醇方剂
CN1799582A (zh) 降血糖、降血压的药物
Singhai et al. The potential of natural products in the management of cardiovascular disease
CN104042684A (zh) 一种含有绞股蓝提取物的中药组合物及制备方法
CN103505664A (zh) 一种含有决明子的降血脂组合物及制备方法
CN102743458A (zh) 一种调节血脂、增加免疫力的保健药物配方
CN101053598B (zh) 一种防治心脑血管疾病及糖尿病的药物组合物
CN103505507A (zh) 一种含有灵芝的中药组合物及制备方法
CN103505505A (zh) 一种含有银杏叶的降血脂组合物及制备方法
US8980340B1 (en) Medicinal composition of extract of seed of emblica officinalis and method of preparing the same
Hoq A cardio protective medicinal plant Terminalia arjuna: evidence from the traditional medicine and recent research
Velmani et al. Multifaceted Medicinal Properties of Queen of the Herbs (Asparagus racemosus): An Overview
RU2773856C1 (ru) Средство, обладающее гипогликемическим действием, и способ его получения
RU2773856C9 (ru) Средство, обладающее гипогликемическим действием, и способ его получения
JPS60260520A (ja) 医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201215